Market Place
Sourcing Support
Vertex inks long-term access deal for CF meds in Englan
22 Jun 2024 //
FIERCE PHARMA
Vertex: TRIKAFTA® Benefit Data At Cystic Fibrosis Conference
07 Jun 2024 //
BUSINESSWIRE
Vertex`s sales of Trikafta hit $8.9B thanks to label expansion
06 Feb 2024 //
FIERCE PHARMA
Vertex meets own cystic fibrosis record with next-gen treatment
06 Feb 2024 //
FIERCE BIOTECH
Vertex Announces EMA Validation for MAA Extension for KAFTRIO
24 Nov 2023 //
BUSINESSWIRE
EC Approves KAFTRIO® in Combination With Ivacaftor
23 Nov 2023 //
BUSINESSWIRE
NICE rejects cost effectiveness of Vertex`s cystic fibrosis meds
07 Nov 2023 //
FIERCE PHARMA
Vertex Receives CHMP Positive Opinion for KAFTRIO
15 Sep 2023 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With Cystic Fibrosis
27 Apr 2023 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA in Children With CF
26 Apr 2023 //
BUSINESSWIRE
Health Canada Grants Marketing Authorization for TRIKAFTA
20 Apr 2022 //
BUSINESSWIRE
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA
26 Mar 2022 //
BUSINESSWIRE
European Commission approves cystic fibrosis treatment for six to 11-year-olds
11 Jan 2022 //
PHARMATIMES
Vertex Signs Reimbursement Agreement for KAFTRIO+Ivacaftor in Cystic Fibrosis
19 Nov 2021 //
BUSINESSWIRE
Vertex Announces Letter of Intent With pan-Canadian Pharmaceutical Alliance
17 Sep 2021 //
BIOSPACE
Vertex Announces Publication in The New England Journal of Medicine
26 Aug 2021 //
BUSINESSWIRE
Health Canada Grants Marketing Authorization for TRIKAFTA
18 Jun 2021 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA
09 Jun 2021 //
BUSINESSWIRE
Vertex’s CF drug Trikafta shines but analysts bemoan pipeline
02 Feb 2021 //
FIERCEPHARMA
Vertex Announces FDA Approvals of TRIKAFTA® , SYMDEKO® and KALYDECO®
21 Dec 2020 //
BIOSPACE
Vertex to Present New Data at Virtual Cystic Fibrosis Conferences
24 Sep 2020 //
BUSINESSWIRE
ICER Issues Report& Policy Recommendations on Treatments for Cystic Fibrosis
23 Sep 2020 //
PRESS RELEASE
Vertex’s Kaftrio approved for use in Europe and made accessible on the NHS
26 Aug 2020 //
EUROPEANPHARMACEUTICALREVIEW
Vertex and NHS Wales agree on Kaftrio reimbursement
24 Jul 2020 //
PHARMA TIMES
Vertex Announces Expansion of Reimbursement Agreement With NHS KAFTRIO ®
30 Jun 2020 //
PRESS RELEASE
EMA recommends eight new medicines, refuses one
27 Jun 2020 //
RAPS
CHMP Grants Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor)
26 Jun 2020 //
BUSINESSWIRE
Amid COVID-19, Vertex lifts sales projections thanks to Trikafta
30 Apr 2020 //
FIERCE PHARMA
Former Vertex CEO Leiden scored $18.8M in 2019
29 Apr 2020 //
FIERCE PHARMA
Vertex’s new cystic fibrosis drug needs to be far cheaper to be cost effective
29 Apr 2020 //
ENDPTS
ICER Releases Evidence Report on Treatments for Cystic Fibrosis
28 Apr 2020 //
ICER-REVIEW
Vertex impresses with strong Trikafta launch
01 Feb 2020 //
BIOPHARMADIVE
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
27 Nov 2019 //
RAPS
‘Impressive’ results for Trikafta in cystic fibrosis
02 Nov 2019 //
PHARMATIMES
Vertex is `humming` with triple combo launch Trikafta underway
31 Oct 2019 //
FIERCE BIOTECH
Vertex Announces EMA Marketing Authorization Application Validation for VX-445
31 Oct 2019 //
BUSINESSWIRE
Phase 3 Results from Two Studies of TRIKAFTA
31 Oct 2019 //
BUSINESSWIRE
Trikafta wins FDA approval for CF (Approval)
22 Oct 2019 //
PHARMATIMES
FDA Approves Cystic Fibrosis Drug Applicable For 90 Percent Of Patients
22 Oct 2019 //
FORBES
FDA approves new breakthrough therapy for cystic fibrosis
22 Oct 2019 //
FDA
Vertex ushers in CF triple combo era with Trikafta approval
22 Oct 2019 //
FIERCE PHARMA
Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review
21 Oct 2019 //
RAPS
FDA Grants Priority Review to Vertex’s 1st Triple Combo for CF
27 Aug 2019 //
CYSTICFIBROSISNEWS TODAY
FDA Accepts NDA for VX-445 (Elexacaftor), Tezacaftor& Ivacaftor Combo
20 Aug 2019 //
BUSINESSWIRE
FDA Accepts New Drug Application for VX-445 (Elexacaftor) Tezacaftor & Ivacaftor
20 Aug 2019 //
BUSINESSWIRE
